Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Beam Therapeutics Inc. Common Stock

BEAM

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Last trade $20.76
Day change -$0.18 (-0.86%)
Day range $20.57 – $21.97
Volume 1,424,656
Market cap $2.17B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$2.17B
Price / earnings
—
Price / book
2.27×
Price / sales
14.78×
EV / sales
14.01×
EV / EBITDA
-5.54×

Profitability

Earnings per share
-$1.03
Return on assets
-8.44%
Return on equity
-11.24%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.11×
Current ratio
13×
Quick ratio
13×
Cash ratio
2.6×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$398.24M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for BEAM, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$307K$490K$31.74M$114.11M$9.7M$8.47M$7.47M$30.07M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$307K$490K$31.74M$114.11M$9.7M$8.47M$7.47M$30.07M
Selling, general and administrative$31.52M$31.95M$34.43M$32.28M$26.74M$26.86M$27.94M$28.66M
Research and development$110.11M$95.1M$104.52M$99.28M$109.77M$101.76M$98.82M$101.44M
Total operating expenses$141.63M$127.25M$138.95M$131.55M$136.51M$128.65M$126.76M$130.1M
Operating income-$141.32M-$126.76M-$107.22M-$17.45M-$126.81M-$120.18M-$119.29M-$100.04M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$134.41M-$122.68M-$94.32M$244.3M-$112.57M-$102.14M-$108.33M-$90.35M
Income taxes$0$0$0$0$0$0$0$0
Net income-$134.41M-$122.68M-$94.32M$244.3M-$112.57M-$102.14M-$108.33M-$90.35M
Net income attributable to common shareholders-$134.41M-$122.68M-$94.32M$244.3M-$112.57M-$102.14M-$108.33M-$90.35M
EBITDA-$135.88M-$121.35M-$101.61M-$11.78M-$121.25M-$114.64M-$113.76M-$94.59M
Basic earnings per share-$1.28-$1.18-$0.91$2.37-$1.10-$1.00-$1.23-$1.09
Diluted earnings per share-$1.28-$1.18-$0.91$2.37-$1.10-$1.00-$1.23-$1.09

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

BEAM Stock Falls 7% Despite Meeting Primary Endpoints in SCD Study

Beam Therapeutics reported positive top-line results from its BEACON study for risto-cel, a gene-editing therapy for sickle cell disease, achieving primary efficacy and safety endpoints with patients demonstrating freedom from severe vaso-occlusive crises for at least 12 consecutive months. The company plans to submit a biologics license application to the FDA by end of 2026, potentially marking the first commercial product approval for a base-editing therapy. Despite the encouraging clinical results, BEAM shares declined 7% following the announcement, likely due to concerns over weaker third-quarter results and profit-taking.

GlobeNewswire Inc.

Sickle Cell Disease Clinical Trial Pipeline Gains Momentum: 45+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Over 45 pharmaceutical companies are advancing 50+ pipeline drugs for sickle cell disease treatment. Key developments include Agios Pharmaceuticals' mitapivat receiving FDA Priority Review, Novo Nordisk's etavopivat meeting Phase III endpoints, and CorrectSequence Therapeutics' CS-206 showing sustained vaso-occlusive crisis-free results. The pipeline features diverse mechanisms including PK activators, gene therapies, and fetal hemoglobin stimulants, with approximately 5+ drugs in late-stage development.

Zacks Investment Research

Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?

Beam Therapeutics (BEAM) shares surged 15.6% following positive early-stage data for its experimental gene-editing treatment BEAM-301 for glycogen storage disease type Ia. The treatment showed improvements in fasting tolerance and glucose control in six patients, with two patients no longer requiring daily starch supplements. Despite some serious adverse events, the company plans to test higher doses and pursue FDA approval discussions. However, earnings estimate revisions remain unchanged, which may limit sustained momentum.

The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood's Ark Invest added to positions in Meta Platforms, Airbnb, and Beam Therapeutics on Monday. Meta surged 11% on momentum from its new Muse AI app and an upgraded price target from Wells Fargo. Airbnb continues strong revenue growth despite headwinds from rising travel costs and regulatory scrutiny. Beam Therapeutics is recovering after recent clinical trial data showed efficacy in its gene-editing treatment for alpha-1 antitrypsin deficiency.

GlobeNewswire Inc.

Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences

Beam Therapeutics announced management participation in three major investor conferences in September 2026. The company also reported progress on its BEAM-302 trial in Alpha-1 Antitrypsin Deficiency, with dosing completed for adult and adolescent patients and updated data selected for presentation at the European Respiratory Society Congress 2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Feb 4, 2014$0.225Mar 3, 2014recurring
Nov 4, 2013$0.225Dec 2, 2013recurring
Aug 12, 2013$0.23Sep 3, 2013recurring
May 6, 2013$0.225Jun 3, 2013recurring
Feb 4, 2013$0.225Mar 1, 2013recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.